CA-ANDERSEN-GLOBAL
De latinamerikanske medlemsfirmaer i Andersen Global vil nu operere under navnet ”Andersen”, hvilket styrker organisationens position som en one-stop-shop for skattemæssige og juridiske tjenester globalt. Meddelelsen kommer mindre end to måneder efter, at de europæiske medlemsfirmaer i Andersen Global antog Andersen-navnet.
Andersen Globals medlemsfirmaer i Brasilien, Ecuador, Guatemala, Mexico og Uruguay, der tidligere opererede under navnene, ”Andersen Tax” og ”Andersen Tax & Legal,” har nu Andersen som deres navn sammen med de nye medlemsfirmaer, MODO Law og GSRC i Argentina, der blev medlemsfirmaer i organisationen tidligere på året.
Andersen Global fortsætter med at betragte udvidelse af både sit fodaftryk i Latinamerika og sin nyetablerede platform i Caribien som høje prioriteter. I Latinamerika har den globale organisation også en tilstedeværelse i Chile, Colombia, Costa Rica, El Salvador, Honduras, Nicaragua, Panama, Paraguay og Peru gennem sine samarbejdsfirmaer, og har tilføjet samarbejdsfirmaer i 11 lande i Caribien i løbet af de sidste seks måneder.
”Vores ekspansion er drevet af kundeservice, og vores målsætning er ikke at være det største firma, snarere handler vores fokus om vores engagement i at opbygge et firma, hvor kunder får uovertrufne skattemæssige og juridiske tjenester på en sømløs måde overalt i verden,” sagde bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz. ”Vores organisation er ikke kun dedikeret til vores kunder, men også til at investere i vores medarbejdere og den næste generation. Vi deler alle de samme værdier og den samme vision uanset grænser, og det er kun passende, at dette også afspejles i vores navn.”
Organisationens rejse begyndte i 2002, da 23 tidligere Arthur Andersen-partnere oprettede skattefirmaet WTAS. I 2014 antog det amerikanske medlemsfirma navnet “Andersen Tax” og overgik for nylig til Andersen-navnet i 2019. Den globale organisation er vokset eksponentielt siden etableringen af Andersen Global (tidligere WTAS Global) af det grundlæggende amerikanske medlem Andersen Tax LLC i 2013. Efter lanceringen af sin globale platform i Europa debuterede Andersen Global i Latinamerika i 2015. Regionen er siden vokset til mere end 34 lokaliteter, 1.000 skatte- og juraeksperter, og 90 partnere i dag.
Leonardo Mesquita, regional administrerende direktør for Latinamerika tilføjede, ”Vores organisations fundament er baseret på vores fælles vision om at forblive uafhængige og levere sømløse, synergistiske tjenester til vores kunder globalt. Vi glæder os til at have et navn, der afspejler det, vi allerede ved – vi er ét firma.”
I løbet af det næste år fortsætter medlemsfirmaer globalt med at antage Andersen-navnet, mens Andersen Global fortsætter sin ekspansionsindsats på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.
Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter fra hele verden. Siden oprettelsen i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på over 191 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200826005393/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
